Thursday 7 May, 2026
Objectives: Parkinson’s disease (PD) – the second most prevalent neurodegenerative disorder worldwide [1] – is characterized by the progressive accumulation…
Read morePoster: Drug/Disease Modelling - CNS
POPULATION PHARMACOKINETIC ANALYSIS OF ORAL, INTRAMUSCULAR IMMEDIATE RELEASE AND SUBCUTANEOUS LONG-ACTING INJECTABLE OLANZAPINE
Thursday 7 May, 2026
Introduction/Objectives: Olanzapine is an antipsychotic drug used in the treatment of schizophrenia with oral (PO) and intramuscular (IM) formulations currently…
Read morePredicting Total Immunoglobulin G When Switching From Efgartigimod To Nipocalimab
Thursday 7 May, 2026
Introduction: Neonatal Fc Receptor (FcRn), which mediates immunoglobulin G (IgG) recycling, is a promising target for treatment of auto-immune diseases….
Read moreMODEL-BASED BRIDGING OF EPLONTERSEN POPULATION PHARMACOKINETICS AND PHARMACODYNAMICS IN CHINESE HEALTHY VOLUNTEERS AND CHINESE PATIENTS WITH HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS WITH POLYNEUROPATHY SUPPORTS GLOBAL DOSING REGIMEN WITHOUT DOSE ADJUSTMENT
Thursday 7 May, 2026
Objectives Eplontersen is an antisense oligonucleotide-GalNAc conjugate that reduces the amount of circulating transthyretin (TTR) protein by binding to TTR…
Read moreBayesian PBPK modeling for acyclovir dose optimization for treating viral encephalitis
Thursday 16 October, 2025
Introduction/Objectives: Viral encephalitis is a rare but life-threatening central nervous system (CNS) infection commonly caused by herpesviruses with a mortality rate…
Read moreIntegrated Population PK and PBPK Modelling Approaches of IAMA-6 Plasma Concentrations following Oral, Intraperitoneal and Intravenous Administrations in Three Different Preclinical Species for First in Human Dose Prediction
Thursday 16 October, 2025
Introduction/Objectives: IAMA-6 is a small molecule, selective inhibitor of the sodium potassium chloride cotransporter (NKCC1), showing encouraging in vitro and in vivo…
Read moreA population pharmacokinetic model of N,N-dimethyltryptamine administered through continuous intravenous infusion in healthy smokers and non-smokers
Thursday 16 October, 2025
Introduction: Psychedelic agents such as N,N-dimethyltryptamine (DMT) are currently being studied for the treatment of various mental disorders [1][2]. To…
Read moreExposure-Response Analysis of Centanafadine Sustained Release Tablets in Adults with Attention-Deficit/Hyperactivity Disorder
Thursday 16 October, 2025
Objectives: Centanafadine is a small-molecule with inhibitory activity at norepinephrine, dopamine, and serotonin reuptake transporters and is under development for…
Read moreExploring the contribution of brain metabolism in mechanistic understanding of Kp,uu,BBB – A case study for remoxipride
Thursday 16 October, 2025
Objectives: Kp,uu,BBB values are crucial indicators of drug distribution into the brain, representing the steady-state relationship between unbound concentrations in…
Read moreNatural disease progression model with transition probabilities to describes the continuum of Alzheimer’s disease
Thursday 16 October, 2025
Introduction and objectives Understanding the natural Alzheimer`s Disease (AD) progression is important for developing disease modifying therapies [1]. Limited knowledge…
Read more